NeRRe Therapeutics Announces Publication of Positive Results in a Phase 2 Pilot Study of Orvepitant in Chronic Refractory Cough

NeRRe Therapeutics Announces Publication of Positive Results in a Phase 2 Pilot Study of Orvepitant in Chronic Refractory Cough

NeRRe Therapeutics is pleased to report that the positive Phase 2 pilot study of orvepitant in Chronic Refractory Cough has been published online on August 14th in the leading respiratory journal CHEST – the official publication of the American College of Chest Physicians. The article is entitled: The Neurokinin-1 Receptor Antagonist Orvepitant is a Novel Antitussive Therapy for Chronic Refractory Cough: Results from a Phase 2 Pilot Study (VOLCANO-1).

The paper describes that in this Phase 2 trial (called VOLCANO-1) involving patients suffering from Chronic Refractory Cough, orvepitant treatment for 4-weeks resulted in a rapid, significant and sustained improvements in objective cough frequency, cough severity VAS, and Quality of Life scores. Orvepitant was safe and well tolerated in the study.

NeRRe is currently preparing to initiate a Phase 3 program with orvepitant in Refractory Chronic Cough or Unexplained Chronic Cough following successful completion of a Phase 2b dose ranging study (VOLCANO-2).